2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Clinical Guidelines, Practice Models, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Measurable Residual Disease, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult, Elderly
PAPER

3709 Early responses and frequent mcd classification with first-line polatuzumab vedotin–based therapy in DLBCL involving selected high-risk extranodal sites: A real-world cohort

Fenghua Gao Jr, MD, quande Lin, PhD2, Jianwei Du3, Lihua Dong4, Xiaoyan Lin5, Yifei Chen, MD6, tao Liu7, Ruijie Li8, Zhihui Li, MD9, Genjie Wang, N/A10, Ning Hu11, chao Li, N/A12, Xingchen Liu, MD13, Xueli Jiao, MD14, Qianying Pan, MD15, Qing Zhang, MD16, Hao Guo, MD, PhD17, Jingyi Yang, MD18, Ran Zhao, MD19, Keshu Zhou, PhD20
1 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, China
2 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, China
3 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, China
4 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, China
5 Puyang Oilfield General Hospital, Puyang, China
6 Jiangdu People's Hospital Affiliated to Yangzhou University, Yangzhou, China
7 Zhoukou Central Hospital, Zhoukou, China
8 Henan Provincial Chest Hospital (Chest Hospital Affiliated to Zhengzhou University), Zhengzhou, China
9 Xinxiang Central Hospital, Xinxiang, China
10 The First People's Hospital of Shangqiu, Shangqiu, China
11 HuaiHe Hospital of Henan University, Kaifei, China
12 Nanyang Central Hospital, Nanyang, China
13 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, China
14 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, China
15 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, China
16 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, China
17 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, China
18 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, China
19 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, China
20 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, China

Background

Diffuse large B-cell lymphoma (DLBCL) involving selected high-risk extranodal sites, including the central nervous system (CNS), testis, and breast, has distinct clinical behavior and an increased risk of extranodal or sanctuary-site relapse. CNS- and testicular-involved DLBCL frequently harbor MYD88/CD79B-associated molecular features, including the LymphGen MCD subtype. However, real-world outcomes with first-line polatuzumab vedotin (pola)–based therapy and the molecular composition of this population remain insufficiently characterized. We evaluated early treatment responses and LymphGen classifications in patients with DLBCL involving these sites.

Methods

Patients with newly diagnosed DLBCL receiving first-line pola-based therapy were categorized into three mutually exclusive groups: involvement of selected high-risk extranodal sites comprising the CNS, testis, or breast, including multisite combinations; other extranodal involvement; and no extranodal involvement.

Patients were considered response-evaluable after completing at least 3 treatment cycles. Responses were investigator-assessed by PET-CT after cycles 3 and 6, and the best overall response rate (ORR) and complete response (CR) rate available at data cutoff were summarized. Available tumor sequencing data were analyzed using the LymphGen classification system. Given the small site-specific subgroup and immature follow-up, all analyses were considered descriptive and hypothesis-generating.

Results

Among 497 patients receiving first-line pola-based therapy, 37 had involvement of the CNS, testis, or breast, 345 had other extranodal involvement, and 115 had no extranodal involvement. At data cutoff, 28 of 37 patients (75.7%), 270 of 345 patients (78.3%), and 93 of 115 patients (80.9%), respectively, were response-evaluable.

The selected-site subgroup had a high-risk clinical profile, with a median age of 63 years and an International Prognostic Index score of 3–5 in 64% of patients. Among the 28 response-evaluable patients, the ORR was 100% and the CR rate was 82%. The corresponding ORR and CR rates were 95% and 62% in patients with other extranodal involvement and 98% and 73% in patients without extranodal involvement. Thus, the selected-site subgroup demonstrated a numerically high early CR rate despite its adverse baseline clinical features. However, these unadjusted response comparisons should be interpreted cautiously because of the small subgroup size and immature survival follow-up.

Involved sites included the CNS, testis, breast, and multisite combinations involving one of these organs. Among 17 patients with available sequencing, LymphGen classifications were MCD in 8 patients (47%), NOS in 4, A53 in 3, BN2 in 1, and unclassified in 1. MCD was therefore the most frequently identified molecular subtype in the molecularly evaluable subgroup.

Conclusions

In this exploratory real-world cohort, patients with DLBCL involving the CNS, testis, or breast demonstrated a high early response rate following first-line pola-based therapy, with an ORR of 100% and a CR rate of 82% among response-evaluable patients. MCD was the most frequently identified LymphGen subtype, occurring in 8 of 17 molecularly evaluable patients, consistent with the recognized molecular features of CNS- and testicular-involved DLBCL.

These findings should not be interpreted as establishing MCD as a predictive biomarker of pola benefit. Longer follow-up, site-specific analyses, standardized assessment of CNS-directed treatment, and comparative molecular data are required to determine response durability, survival outcomes, and patterns of sanctuary-site relapse.

Fenghua Gao Jr, MD: No relevant conflicts of interest to declare.